"Indonesia Pharmaceuticals & Healthcare Report Q3 2014" is now available at Fast Market Research

While the implementation of universal health coverage will benefit the general population through increased access to medical services, we highlight the need to evaluate whether existing health facilities have the capacity to handle more patients. I ndonesia's strategy of limiting healthcare expenditure through low levels of reimbursement will impede its progress in implementing universal healthcare coverage, as hospitals and medical professional will not be sufficiently compensated.

Headline Expenditure Projections

* Pharmaceuticals: IDR63,806bn (USD6.11bn) in 2013 to IDR69,669bn (USD6.18bn) in 2014; +9.2% growth in local currency terms and +1.2% in US dollar terms. Forecast broadly in line with previous quarter.
* Healthcare: IDR285,776bn (USD27.35bn) in 2013 to IDR325,404bn (USD28.87bn) in 2014; +13.9% growth in local currency terms and +5.6% in US dollar terms. Forecast upgraded due to data from the World Health Organization.

Full Report Details at
- http://www.fastmr.com/prod/850871_indonesia_pharmaceuticals_healthcare_report_q3.aspx?afid=302

Risk/Reward Rating

In our latest Q314 proprietary Pharmaceutical Risk/Reward Rating (RRR) ratings, Indonesia ranks 13th out of the 19 Asia Pacific markets. Though its Rewards are considered to be above than the regional average, Indonesia's Risks profile is considerably more unfavourable, which will continue to detract foreign players from investing in the country's pharmaceutical market.

Key Trends And Developments

* In May 2014 , Standard Chartered Private Equity (SCPE), the private equity and venture capital arm of Standard Chartered, in partnership with Elang Mahkota Teknologi Tbk (Emtek) will invest USD50mn to develop Emtek's healthcare business in Indonesia. Under the partnership, Emtek and SCPE aim to provide quality healthcare services to the Indonesian population through EMC's chain of hospitals.
* In April 2014, Health Minister Nafisah Mboi announced that a process is underway to revise Permenkes No. 69/2013, as health facilities and medical workers receive less than the cost of procedures. According to Said...

The Indonesia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Indonesia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Indonesian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Indonesia to test other views - a key input for successful budgeting and strategic business planning in the Indonesian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q3 2014
- Moldova Pharmaceuticals & Healthcare Report Q3 2014
- Peru Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014
- Turkey Pharmaceuticals & Healthcare Report Q3 2014